Home Articoli
Linee guida per la valutazione del rischio cardiovascolare e la terapia ipocolesterolemizzante

Best practice

Linee guida per la valutazione del rischio cardiovascolare e la terapia ipocolesterolemizzante
Antonino Cartabellotta, Lora Accettura, Luigi Santoiemma

Evidence 2015;7(3): e1000106 doi: 10.4470/E1000106

Pubblicato: 10 marzo 2015

Copyright: © 2015 Cartabellotta. Questo è un articolo open-access, distribuito con licenza Creative Commons Attribution, che ne consente l’utilizzo, la distribuzione e la riproduzione su qualsiasi supporto esclusivamente per fini non commerciali, a condizione di riportare sempre autore e citazione originale.


Notice: Undefined index: data_varchar in /var/www/www.evidence.it/include/functions.php on line 1507

Notice: Undefined index: data_varchar in /var/www/www.evidence.it/include/functions.php on line 1507
1. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. (Clinical guideline 67) May 2008. Disponibie a: www.nice.org.uk/guidance/CG67. Ultimo accesso 10 marzo 2015.
2. Baigent C, Blackwell I, Emberson J, Holland LE, Reith C, Bhala N, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
3. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
4. Bosch J, Gerstein HC, Dagenais GR, , DĂ­az R, Dyal L, Jung H, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18.
5. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
6. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
7. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. (Clinical guideline 181) July 2014. Disponibile a: www.nice.org.uk/guidance/CG181. Ultimo accesso 10 marzo 2015.
8. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia (FH). (Clinical guideline 71) August 2008. Disponibile a: www.nice.org.uk/guidance/CG071. Ultimo accesso 10 marzo 2015.
9. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
10. National Institute for Health and Clinical Excellence. Hypertension: the clinical management of primary hypertension in adults. (Clinical guideline 127) August 2011. www.nice.org.uk/guidance/CG127. Ultimo accesso 10 marzo 2015.
11. National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. (Clinical guideline 43). December 2006. www.nice.org.uk/guidance/CG43.
12. Department of Health. Putting prevention first. NHS Health Check: vascular risk assessment and management best practice guidance. 2013. www.nhshealthcheck.nhs.uk. Ultimo accesso 10 marzo 2015.
13. Joint British Societies recommendations on the prevention of cardiovascular disease. JBS3 risk calculator 2014. Disponibile a: www.jbs3risk.com/pages/risk_calculator.htm. Ultimo accesso 10 marzo 2015.